Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EBIT (2023 - 2025)

Historic EBIT for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's EBIT fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2622.53%. This contributed to the annual value of -$305.8 million for FY2024, which is 17919.29% down from last year.
  • Immunome's EBIT amounted to -$60.1 million in Q3 2025, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's EBIT peaked at -$4.5 million during Q1 2023, and registered a low of -$132.3 million during Q1 2024.
  • Its 3-year average for EBIT is -$51.5 million, with a median of -$46.5 million in 2025.
  • In the last 5 years, Immunome's EBIT plummeted by 285904.72% in 2024 and then surged by 6626.13% in 2025.
  • Immunome's EBIT (Quarter) stood at -$94.7 million in 2023, then increased by 12.34% to -$83.0 million in 2024, then increased by 27.52% to -$60.1 million in 2025.
  • Its EBIT stands at -$60.1 million for Q3 2025, versus -$46.5 million for Q2 2025 and -$44.6 million for Q1 2025.